These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28817344)

  • 1. A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene Therapies.
    White M; Whittaker R; Gándara C; Stoll EA
    Hum Gene Ther Methods; 2017 Aug; 28(4):163-176. PubMed ID: 28817344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice.
    Gándara C; Affleck V; Stoll EA
    Hum Gene Ther Methods; 2018 Feb; 29(1):1-15. PubMed ID: 29212357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of lentiviral vectors.
    Milone MC; O'Doherty U
    Leukemia; 2018 Jul; 32(7):1529-1541. PubMed ID: 29654266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
    de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
    Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
    Doi K; Takeuchi Y
    Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector.
    Manilla P; Rebello T; Afable C; Lu X; Slepushkin V; Humeau LM; Schonely K; Ni Y; Binder GK; Levine BL; MacGregor RR; June CH; Dropulic B
    Hum Gene Ther; 2005 Jan; 16(1):17-25. PubMed ID: 15703485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II Manufacture of Lentiviral Vectors Under GMP in an Academic Setting.
    Dasgupta A; Tinch S; Szczur K; Ernst R; Shryock N; Kaylor C; Lewis K; Day E; Truong T; Swaney W
    Methods Mol Biol; 2020; 2086():27-60. PubMed ID: 31707666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research.
    Dropulić B
    Hum Gene Ther; 2011 Jun; 22(6):649-57. PubMed ID: 21486177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications.
    Wong LF; Goodhead L; Prat C; Mitrophanous KA; Kingsman SM; Mazarakis ND
    Hum Gene Ther; 2006 Jan; 17(1):1-9. PubMed ID: 16409120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosafety challenges for use of lentiviral vectors in gene therapy.
    Rothe M; Modlich U; Schambach A
    Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of the First World Health Organization Lentiviral Vector Standard: Toward the Production Control and Standardization of Lentivirus-Based Gene Therapy Products.
    Zhao Y; Stepto H; Schneider CK
    Hum Gene Ther Methods; 2017 Aug; 28(4):205-214. PubMed ID: 28747142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral Vectors for Gene Therapy: Translational and Clinical Outlook.
    Kotterman MA; Chalberg TW; Schaffer DV
    Annu Rev Biomed Eng; 2015; 17():63-89. PubMed ID: 26643018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications.
    Kumar P; Woon-Khiong C
    Curr Gene Ther; 2011 Apr; 11(2):144-53. PubMed ID: 21291355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Developments in gene delivery vectors for ocular gene therapy].
    Khabou H; Dalkara D
    Med Sci (Paris); 2015 May; 31(5):529-37. PubMed ID: 26059304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors.
    Follenzi A; Sabatino G; Lombardo A; Boccaccio C; Naldini L
    Hum Gene Ther; 2002 Jan; 13(2):243-60. PubMed ID: 11812281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress in improvement of lentiviral vectors' transcriptional read-through].
    He J; Zhang J
    Sheng Wu Gong Cheng Xue Bao; 2011 Nov; 27(11):1541-8. PubMed ID: 22393708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of advanced therapy medicinal products in Europe and the role of academia.
    Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
    Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient marking of murine long-term repopulating stem cells targeting unseparated marrow cells at low lentiviral vector particle concentration.
    Kurre P; Anandakumar P; Harkey MA; Thomasson B; Kiem HP
    Mol Ther; 2004 Jun; 9(6):914-22. PubMed ID: 15194058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lentiviral vectors in clinical trials: Current status.
    D'Costa J; Mansfield SG; Humeau LM
    Curr Opin Mol Ther; 2009 Oct; 11(5):554-64. PubMed ID: 19806504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.